These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 11234890

  • 1. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
    Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C, Bhalla K.
    Clin Cancer Res; 2001 Feb; 7(2):350-7. PubMed ID: 11234890
    [Abstract] [Full Text] [Related]

  • 2. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells.
    Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K.
    Blood; 2000 Dec 01; 96(12):3900-6. PubMed ID: 11090076
    [Abstract] [Full Text] [Related]

  • 3. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.
    Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, Bhalla KN.
    Blood; 2000 Sep 15; 96(6):2246-53. PubMed ID: 10979973
    [Abstract] [Full Text] [Related]

  • 4. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
    Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, Bhalla K.
    Cancer Res; 2004 Apr 01; 64(7):2580-9. PubMed ID: 15059915
    [Abstract] [Full Text] [Related]

  • 5. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN.
    Cancer Res; 2001 Jan 15; 61(2):759-63. PubMed ID: 11212279
    [Abstract] [Full Text] [Related]

  • 6. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
    Uno K, Inukai T, Kayagaki N, Goi K, Sato H, Nemoto A, Takahashi K, Kagami K, Yamaguchi N, Yagita H, Okumura K, Koyama-Okazaki T, Suzuki T, Sugita K, Nakazawa S.
    Blood; 2003 May 01; 101(9):3658-67. PubMed ID: 12506034
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells.
    Griffin D, Wittmann S, Guo F, Nimmanapalli R, Bali P, Wang HG, Bhalla K.
    Gynecol Oncol; 2003 Apr 01; 89(1):37-47. PubMed ID: 12694652
    [Abstract] [Full Text] [Related]

  • 10. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K.
    Cancer Res; 2002 Oct 15; 62(20):5761-9. PubMed ID: 12384536
    [Abstract] [Full Text] [Related]

  • 11. TRAIL/Apo-2L: mechanisms and clinical applications in cancer.
    Srivastava RK.
    Neoplasia; 2001 Oct 15; 3(6):535-46. PubMed ID: 11774036
    [Abstract] [Full Text] [Related]

  • 12. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ, Kim MJ, Kim HB, Kang CD, Kim SH.
    Biochem J; 2009 Apr 28; 420(1):73-81. PubMed ID: 19203346
    [Abstract] [Full Text] [Related]

  • 13. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
    Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH.
    Exp Cell Res; 2009 Jul 01; 315(11):1809-18. PubMed ID: 19268463
    [Abstract] [Full Text] [Related]

  • 14. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
    Wang Z, Sampath J, Fukuda S, Pelus LM.
    Cancer Res; 2005 Sep 15; 65(18):8224-32. PubMed ID: 16166298
    [Abstract] [Full Text] [Related]

  • 15. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
    Greene LM, Kelly L, Onnis V, Campiani G, Lawler M, Williams DC, Zisterer DM.
    J Pharmacol Exp Ther; 2007 Apr 15; 321(1):288-97. PubMed ID: 17202400
    [Abstract] [Full Text] [Related]

  • 16. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
    Perkins C, Kim CN, Fang G, Bhalla KN.
    Blood; 2000 Feb 01; 95(3):1014-22. PubMed ID: 10648417
    [Abstract] [Full Text] [Related]

  • 17. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S.
    Cancer Res; 2002 Jan 01; 62(1):188-99. PubMed ID: 11782377
    [Abstract] [Full Text] [Related]

  • 18. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [Abstract] [Full Text] [Related]

  • 19. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.
    Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K.
    Blood; 1998 Mar 01; 91(5):1700-5. PubMed ID: 9473236
    [Abstract] [Full Text] [Related]

  • 20. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
    Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K.
    Blood; 2003 Apr 15; 101(8):3236-9. PubMed ID: 12446442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.